Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis
Loading...
Download
Associated Records
Authors
File Licence
Editors
Date
2017-03-01
Source Title
Journal of Neurology, Neurosurgery and Psychiatry
Journal Title
Journal ISSN
Volume Title
Publisher
BMJ PUBLISHING GROUP
Melbourne Authors
Affiliation
Medicine (RMH)
Document Type
Journal Article
Subject Code
Citation
Lizak, N., Lugaresi, A., Alroughani, R., Lechner-Scott, J., Slee, M., Havrdova, E., Horakova, D., Trojano, M., Izquierdo, G., Duquette, P., Girard, M., Prat, A., Grammond, P., Hupperts, R., Grand'Maison, F., Sola, P., Pucci, E., Bergamaschi, R., Oreja-Guevara, C. ,... Kalincik, T. (2017). Highly active immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced multiple sclerosis. Journal of Neurology Neurosurgery and Psychiatry, 88 (3), pp.196-203. https://doi.org/10.1136/jnnp-2016-313976.
Access Status
Open Access
Access URL
Open Access URL
Open Access at PMC
Linked Resource URL
NHMRC Grant Code
ARC Grant Code
Description
Abstract
OBJECTIVE: To evaluate variability and predictability of disability trajectories in moderately advanced and advanced multiple sclerosis (MS), and their modifiability with immunomodulatory therapy. METHODS: The epochs between Expanded Disability Status Scale (EDSS) steps 3-6, 4-6 and 6-6.5 were analysed. Patients with relapse-onset MS and having reached 6-month confirmed baseline EDSS step (3/4/6) were identified in MSBase, a global observational MS cohort study. We used multivariable survival models to examine the impact of disease-modifying therapy, clinical and demographic factors on progression to the outcome EDSS step (6/6.5). Sensitivity analyses with varying outcome definitions and inclusion criteria were conducted. RESULTS: For the EDSS 3-6, 4-6 and 6-6.5 epochs, 1560, 1504 and 1231 patients were identified, respectively. Disability trajectories showed large coefficients of variance prebaseline (0.92-1.11) and postbaseline (2.15-2.50), with no significant correlations. The probability of reaching the outcome step was not associated with prebaseline variables, but was increased by higher relapse rates during each epoch (HRs 1.58-3.07; p<0.001). A greater proportion of each epoch treated with higher efficacy therapies was associated with lower risk of reaching the outcome disability step (HRs 0.72-0.91 per 25%; p≤0.02). 3 sensitivity analyses confirmed these results. CONCLUSIONS: Disease progression during moderately advanced and advanced MS is highly variable and amnesic to prior disease activity. Lower relapse rates and greater time on higher efficacy immunomodulatory therapy after reaching EDSS steps 3, 4 and 6 are associated with a decreased risk of accumulating further disability. Highly effective immunomodulatory therapy ameliorates accumulation of disability in moderately advanced and advanced relapse-onset MS.